Studying How Watching a Video Affects Patient Experience During First Intravitreal Anti-VEGF Injection for Retinal Diseases
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-06-03
182
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether watching an educational video before receiving an intravitreal anti-VEGF injection can improve the experience for patients and reduce the occurrence and size of subconjunctival hemorrhage. This study focuses on individuals with retinal diseases such as age-related macular degeneration, diabetic retinopathy, choroidal neovascularization, retinal vein occlusion, and cystoid macular edema who are receiving their first injection. The trial is interventional and randomized, aiming to assess patient anxiety and satisfaction alongside clinical outcomes.
Participants are randomly assigned to one of two groups one group will watch a procedural video explaining the injection process before treatment, while the control group will not view any video. The intervention is behavioral, involving the video viewing prior to the intravitreal injection of anti-VEGF medication. This structured approach allows researchers to compare the impact of video education on patient outcomes.
During the study, all participants will complete the State-Trait Anxiety Inventory-State STAI-S questionnaire before and after the injection to measure changes in anxiety levels. Researchers will also evaluate the rate and area of subconjunctival hemorrhage three minutes after the injection procedure. The trials total duration and follow-up periods are not specified, but assessments focus on immediate post-procedure outcomes and patient experience metrics. This trial is sponsored by the Second Affiliated Hospital, School of Medicine, Zhejiang University.
CONDITIONS
Brief Title
Effect of Video Viewing on Intravitreal Injection Experience
Research Team
X
Xiaoyun Fang, MD., PhD.
F
Fang Zheng, MD., PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients who are receiving their first intravitreal injection of anti-VEGF medication due to retinal diseases
Mentally competent, and able to communicate without barriers
Willing to voluntarily sign an informed consent form.
You will not qualify if you...
History of previous eye surgery
Best-corrected visual acuity in the better eye worse than 0.3
The target eye is complicated with neovascular glaucoma
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 1 day
Participants receive an intravitreal anti-VEGF injection. Some participants watch an educational video about the procedure before treatment, while others do not view the video.
1 treatment visit (in-person)
Follow-up
Duration - Approximately 30 minutes on treatment day
Participants are assessed for subconjunctival hemorrhage shortly after the injection and anxiety levels before and after the procedure.
1 follow-up visit (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Evaluating Intravitreal EYE201MK-8748 Compared to Aflibercept in Treating Neovascular Age-Related Macular Degeneration A Randomized, Double-Masked Clinical Trial
Study Comparing Eye Injection Treatments Tiespectus and Aflibercept for Wet Age-Related Macular Degeneration in Adults 50 and Older
Evaluating MK-8748 Compared to Aflibercept via Eye Injections for Diabetic Macular Edema
Evaluating MK-8748 Compared to Aflibercept for Treating Diabetic Macular Edema in a Randomized, Double-Masked Phase 3 Study
Safety and Dose Escalation Study of Intravitreal THN391 for Diabetic Macular Edema Secondary to Diabetic Retinopathy
Safety, Tolerability, and Pharmacokinetics of RO7663498 Eye Injections in Adults With Diabetic Retinopathy A Multicenter, Open-Label, Multiple-Dose Study
CRIMSON Trial to Study Safety and Effectiveness of Different Dosing Schedules of BI 764524 in Adults With Moderate to Severe Non-proliferative Diabetic Retinopathy
Effectiveness of Switching from Ranibizumab to Aflibercept in Adults 50 and Older with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
AI-powered Portable Fundus Camera Screening for Diabetic Retinopathy in Primary Care Settings
Study of Eye Biomarkers in Adults With Chorioretinal Diseases Including Diabetic Retinopathy and Macular Degeneration